Public Reimbursement of Trikafta Nears in Canada

Vertex Pharmaceuticals has signed a letter of intent with the pan-Canadian Pharmaceutical Alliance (pCPA), which is an agreement in principle to extend public reimbursement to Trikafta, a triple-combination therapy for eligible cystic fibrosis (CF) patients. The extension adds to the letter of intent (LOI) with the pCPA for…